SCHEMBL14412911

SCHEMBL14412911

COc1ccc(CC2CNC(=O)N2Cc2ccccc2)cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.46
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
HTT P42858 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
MAPT P10636 2/20 0.45
ALDH1A1 P00352 1/20 0.45
HSD17B10 Q99714 1/20 0.45
KDM4C Q9H3R0 1/20 0.45
KMT2A Q03164 2/20 0.45
HSD11B1 P28845 1/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
SIRT2 Q8IXJ6 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13986107 0.82 EHMT2 (0.46) MAPTKMT2APOLBNPSR1
SCHEMBL8705856 0.80 KMT2A (0.42) PDE4APDE4BPDE4CPDE4DKMT2A
SCHEMBL13986145 0.76 PDE4A (0.55) MAPK1PDE4APDE4BPDE4CPDE4D
SCHEMBL27952135 0.74 REV1 (0.50) MAPTALDH1A1HSD17B10KDM4CSIRT2
SCHEMBL14412777 0.74 PDE4A (0.54) MAPK1PDE4APDE4BPDE4CPDE4D
SCHEMBL27952036 0.73 HSD17B10 (0.53) MAPK1HTTMAPTALDH1A1HSD17B10
SCHEMBL27939972 0.73 HSD17B10 (0.53) MAPK1HTTMAPTALDH1A1HSD17B10
SCHEMBL11373957 0.73 MAPK1 (0.64) MAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL27940072 0.73 SIGMAR1 (0.52) MAPK1SIGMAR1ALDH1A1HSD17B10KMT2A
SCHEMBL27940132 0.73 SIGMAR1 (0.52) MAPK1SIGMAR1ALDH1A1HSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070208181-A1 BENZYLATED PDE4 INHIBITORS INFLAZYME PHARMACEUTICALS LTD. (CA) 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208181-A1 BENZYLATED PDE4 INHIBITORS PDE4B, PDE4A, PDE3B MAPK1 1008/4885PDE4A 2/4885PDE4B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.